

AMENDMENTS TO THE CLAIMS

Claims 1-4 (Canceled)

5. (Currently amended) A method of treating an allergen-induced inflammatory disorder in a mammal, ~~consisting essentially of~~comprising the step of administering to a mammal that is exposed to an allergen a therapeutically effective amount of a composition consisting essentially of lactoferrin- and a pharmaceutically acceptable carrier~~product~~, said amount being sufficient to reduce inflammation-induced Langerhans cell migration or accumulation of dendritic cells in lymph nodes.

6. (Original) The method of claim 5, wherein the mammal is a human.

7. (Previously presented) The method according to claim 5 wherein the allergen-induced inflammatory disorder features a local immune response characterized by increased production of TNF- α .

8. (Currently amended) The method according to claim 5 wherein the lactoferrin ~~product~~ is a naturally occurring lactoferrin.

9. (Currently amended) The method according to claim 5 wherein the lactoferrin ~~product~~ is a recombinantly produced lactoferrin or a biologically active analog thereof.

10. (Currently amended) The method according to claim 5 wherein the lactoferrin ~~product~~ is a biologically active fragment of lactoferrin.

Claims 11-20 (Canceled)

21. (Currently amended) A method of inhibiting in a mammal a dermal allergen-induced inflammatory response ~~consisting essentially of~~comprising administering to the mammal that is exposed to an allergen a therapeutically effective amount of a composition consisting essentially of lactoferrin~~product~~, said amount being sufficient to reduce inflammation-induced Langerhans cell migration or accumulation of dendritic cells in lymph nodes.

22. Canceled

23. (Previously presented) The method of claim 21, wherein the dermal inflammatory response is mediated by TNF- α .

24. (Previously presented) The method of claim 21, wherein the dermal inflammatory response is further characterized by Langerhans cell migration.

25. Canceled

26. (Previously presented) The method of claim 5, wherein the allergen-induced inflammatory disorder is contact dermatitis.

27. (Previously presented) The method of claim 21, wherein the dermal allergen-induced inflammatory response is manifested as a contact dermatitis.

28. (Previously presented) The method of claim 5, wherein the allergen-induced inflammatory disorder is psoriasis.

29. (Previously presented) The method of claim 21, wherein the dermal allergen-induced inflammatory response is manifested as psoriasis.